Supplementary Table 2. Univariable and multivariable analysis of cohort 2.
| ypCR | ypCR + ypPR | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Univariable analysis | Multivariable analysis | Univariable analysis | Multivariable analysis | |||||||
| ypCR (51) |
Non-ypCR (145) | p value | OR (95%CI) |
p value | ypCR + ypPR (155) | Non-ypCR + ypPR (41) | p value | OR (95%CI) |
p value | |
| Age < 65y ≥ 65y |
36 (70.6%) 15 (29.4%) |
97 (66.9%) 48 (33.1%) |
0.73 | - | - |
106 (68.4%) 49 (31.6%) |
27 (65.9%) 14 (34.1%) |
0.85 | - | - |
| Sex Female Male |
23 (45.1%) 28 (54.9%) |
57 (39.3%) 88 (60.7%) |
0.51 | - | - |
69 (44.5%) 86 (55.5%) |
11 (26.8%) 30 (73.2%) |
0.049 |
2.22 (1.05–4.85) 1 |
0.046 |
| ECOG 0 ≥ 1 Missing |
35 (70.0%) 15 (30.0%) 1 |
96 (66.2%) 49 (33.8%) 0 |
0.73 | - | - |
102 (66.2%) 52 (33.8%) 1 |
29 (70.7%) 12 (29.3%) 0 |
0.71 | - | - |
| Comorbidities No Yes |
10 (19.6%) 41 (80.4%) |
43 (29.7%) 102 (70.3%) |
0.20 | - | - |
47 (30.3%) 108 (69.7%) |
6 (14.6%) 35 (85.4%) |
0.049 |
1 2.62 (1.01–6.79) |
0.047 |
| Clinical stage II III |
12 (23.5%) 39 (76.5%) |
32 (22.1%) 113 (77.9%) |
0.85 |
1.30 (0.55–3.07) 1 |
0.54 |
31 (20.0%) 124 (80.0%) |
13 (31.7%) 28 (68.3%) |
0.14 |
0.50 (0.22–1.05) 1 |
0.09 |
| PPI No Yes |
38 (74.5%) 13 (25.5%) |
106 (73.1%) 39 (26.9%) |
1.00 | - | - |
110 (71.0%) 45 (29.0%) |
34 (82.9%) 7 (17.1%) |
0.16 |
0.48 (0.19–1.20) 1 |
0.12 |
| PPI >50 No Yes |
44 (86.3%) 7 (13.7%) |
125 (86.2%) 20 (13.8%) |
1.00 | - | - |
133 (85.8%) 22 (14.2%) |
36 (87.8%) 5 (12.2%) |
1.00 | - | - |
| Radiotherapy 3D Other |
2 (3.9%) 49 (96.1%) |
18 (12.4%) 127 (87.6%) |
0.11 | 1 0.32 (0.07-1.51) |
0.15 |
16 (10.3%) 139 (89.7%) |
4 (9.8%) 37 (90.2%) |
1.00 | - | - |
| Time RT – surgery ≤ 8 weeks > 8 weeks |
7 (13.7%) 44 (86.3%) |
21 (14.5%) 124 (85.5%) |
1.00 | - | - |
25 (16.1%) 130 (83.9%) |
3 (7.3%) 38 (92.7%) |
0.21 | - | - |
| RT duration ≤ 5 weeks > 5 weeks |
21 (41.2%) 30 (58.8%) |
66 (45.5%) 79 (54.5%) |
0.63 | - | - |
69 (44.5%) 86 (55.5%) |
18 (43.9%) 23 (56.1%) |
1.00 | - | - |
| Dose-intensity 5-FU 100% < 100% |
41 (80.4%) 10 (19.6%) |
121 (83.4%) 24 (16.6%) |
0.67 | - | - |
126 (81.3%) 29 (18.7%) |
36 (87.8%) 5 (12.2%) |
0.49 | - | - |
| Infusional 5-FU No Yes |
7 (13.7%) 44 (86.3%) |
26 (17.9%) 119 (82.1%) |
0.66 | - | - |
27 (11.4%) 128 (82.6%) |
6 (14.6%) 35 (85.4%) |
0.82 | - | - |
| Clinical responsea No Yes Missing |
30 (65.2%) 16 (34.8%) 5 |
118 (90.8%) 12 (9.2%) 15 |
<0.001 |
1 15.21 (2.21-12.31) |
<0.001 |
38 (27.1%) 102 (72.9%) 15 |
8 (22.2%) 28 (77.8%) 5 |
0.67 | - | - |
a
Clinical complete response was used for ypCR analysis and clinical complete + partial response for ypCR + ypPR analysis
ypCR: pathological complete response; ypPR: pathological partial response; OR: odds ratio; 95%CI: 95% CI; y: years; PPI: proton-pump inhibitors; PPI > 50: use of proton-pump inhibitors > 50% of neoadjuvant therapy duration; RT: radiotherapy; 5-FU: 5-fluorouracil
The bold values in represent statistical significant factors associated with ypCR and ypCR+ypPR in univariable and multivariable analysis in cohort 2